Patent application number | Description | Published |
20100247587 | PIGMENTATION-REGULATING COMPOUNDS - The present invention relates to compounds of general formula (I): | 09-30-2010 |
20110002969 | COSMETIC OR PHARMACEUTICAL COMPOSITIONS COMPRISING METALLOPROTEINASE INHIBITORS - Peptides of general formula (I): R | 01-06-2011 |
20110052519 | PEPTIDE DERIVATIVES USEFUL IN THE TREATMENT, CARE OR CLEANSING OF THE SKIN, MUCOSAE, SCALP OR NAILS - The invention relates to peptide derivatives of general formula (I): | 03-03-2011 |
20110300199 | PEPTIDES USED IN THE TREATMENT AND/OR CARE OF THE SKIN, MUCOUS MEMBRANES AND/OR SCALP AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS - Peptides of general formula (I): R | 12-08-2011 |
20120021029 | PEPTIDES USED IN THE TREATMENT AND/OR CARE OF THE SKIN AND/OR HAIR AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS - Peptides of general formula (I): | 01-26-2012 |
20120121675 | COMPOUNDS WHICH INHIBIT MUSCLE CONTRACTION - Peptides of general formula (I): R | 05-17-2012 |
20130078295 | SKIN ANTIAGING TREATMENT - A method for skin antiaging treatment including administering Botulinum toxin to an area of facial and/or neck skin, combined with the administration of a cosmetic or pharmaceutical composition having a cosmetically or pharmaceutically effective amount of at least one peptide derived from the SNAP-25 protein and/or at least one enkephalin-derived peptide, and at least one cosmetically or pharmaceutically acceptable excipient or adjuvant. | 03-28-2013 |
20130101662 | PEPTIDES USED IN THE TREATMENT AND/OR CARE OF THE SKIN, MUCOUS MEMBRANES AND/OR HAIR AND ITS USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS - Peptides of general formula (I): R | 04-25-2013 |
20130309281 | SYNTHETIC PEPTIDES USEFUL IN THE TREATMENT OF THE SKING AND USE THEREOFE IN COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS - The present invention relates to peptides of general formula (I) capable of regulating fibrillogenesis, stereoisomers thereof and mixtures thereof, which may or may not be racemic, and the cosmetically or dermopharmaceutically acceptable salts thereof, wherein Z is alanyl, allo-isoleucyl, glycyl, isoleucyl, isoseryl, isovalyl, leucyl, norleucyl, norvalyl, prolyl, seryl, threonyl, allo-threonyl or valyl; n and m may vary between 1 and 5; AA is selected from the group consisting of natural amino acids encoded in their L- or D-form and non-encoded amino acids; x and y may vary between 0 and 2; R | 11-21-2013 |
20140086981 | PGC-1ALPHA-MODULATING PEPTIDES - Peptides of general formula (I): R | 03-27-2014 |
20140120141 | PEPTIDES USEFUL IN THE TREATMENT AND CARE OF THE SKIN AND MUCOUS MEMBRANES AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS - Peptides of general formula (I), their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, a preparation process, cosmetic or pharmaceutical compositions which contain them and their use for the treatment and/or care of conditions, disorders and/or diseases of the skin and/or mucous membranes. | 05-01-2014 |
20150071974 | COMPOUNDS WHICH INHIBIT NEURONAL EXOCYTOSIS - Compounds of general formula (I): R | 03-12-2015 |
Patent application number | Description | Published |
20080312455 | Method For Determining Enantiomeric Purity Of Darifenacin And Intermediates - The present invention relates to a method for differentiating and quantifying the enantiomers, thereby determining the enantiomeric purity, of darifenacin and its intermediate compounds and salts thereof. In addition, the invention relates to a method for differentiating and quantifying the enantiomers, thereby determining the enantiomeric purity of compounds of formula (I): | 12-18-2008 |
20090018346 | Amorphous Form Of Darifenacin Hydrobromide And Processes For The Preparation Thereof - The present invention relates to amorphous form darifenacin hydrobromide and processes therefor. In addition, the present invention relates to compositions comprising amorphous form darifenacin hydrobromide. | 01-15-2009 |
20090247595 | Process for the preparation of tetrazolyl compounds - The invention provides a method for preparing candesartan cilexetil and related tetrazolyl compounds. More particularly, the invention relates to the preparation of candesartan cilexetil and related tetrazolyl compounds and includes a method of removing a protective group (e.g., triphenylmethane (trityl) protecting group) from an N-protected tetrazolyl compound using a Lewis acid in an inert solvent and in the presence of an alcohol (e.g., reacting an N-protected tetrazolyl compound with ZnCl | 10-01-2009 |
20090253746 | Synthesis and Preparations of Intermediates and New Polymorphs Thereof Useful For The Preparation Of Donepezil Hydrochlcoride - The invention relates to an improved process for preparing 2-(1-benzylpiperidin-4-ylmethyliden)-5,6-dimethoxyin-dan- | 10-08-2009 |
20090306406 | METHOD FOR PREPARING 1,3-DISUBSTITUTED PYRROLIDINE COMPOUNDS - A process for preparing substituted pyrrolidine compounds, including (5)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide hydrobromide, commonly known in the art as darifenacin, comprising reacting a pyrrolidine compound with a benzofuran derivative in the presence of a phase-transfer catalyst. | 12-10-2009 |
20120004239 | Process for Preparing Quinoxaline Derivatives - The present invention provides an improved process for preparing a compound of formula (IIIA), an intermediate of the synthesis of varenicline. Also, the present invention provides an improved process for preparing varenicline, or a pharmaceutically acceptable salt or solvate thereof. Furthermore, the present invention provides a process for decolorizing varenicline, or a salt or solvate thereof. Still further, the present invention provides a process of preparing varenicline L-tartrate with improved yield. Still further, the present invention relates to the use of compound of formula (V), or a salt or solvate thereof, as a reference marker and reference standard for assessing the purity of varenicline, or a salt or solvate thereof. | 01-05-2012 |